Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by LANCKRIET, C
Right arrow Articles by GUÉRIN, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LANCKRIET, C
Right arrow Articles by GUÉRIN, N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 Oxford University Press

research-article

Efficacy of BCG Vaccination of the Newborn: Evaluation by a Follow-Up Study of Contacts in Bangui

C LANCKRIET*, D LÉVY-BRUHL{dagger}, E BINGONO*, R M SIOPATHIS* and N GUÉRIN{dagger}

* Clinique Médicale Infantile, National University Hospital Centre Bangui, Central African Republic
{dagger} International Children's Centre Paris, France

BACKGROUND: The efficacy of Bacillus of Calmette and Guérin (BCG) vaccination given at birth is still controversial. We therefore conducted a study in Bangui (Central African Republic) to estimate the protection afforded over the first seven years of life by BCG administered at birth.

METHODS: One thousand children who had lived in contact with a recently diagnosed case of contagious tuberculosis were followed up for a period of 6 months in order to detect the occurrence of tuberculosis. Diagnosis of tuberculosis was made through a scoring system. Vaccine efficacy (VE) was calculated on the basis of the relative risk of contracting tuberculosis according to vaccination status.

RESULTS: The efficacy of BCG was estimated to be 71% (95% confidence Interval: 56–81%). This result remained practically the same after changing the definition used for tuberculosis cases (VE = 75% for a threshold with a score of 15 instead of 6, VE = 74% when only confirmed cases were considered). There was no difference between the two groups in the variables measuring intensity of contact with the source of contamination, but there was a difference in age distribution. Vaccine efficacy adjusted for this factor was the same as the crude VE.

CONCLUSIONS: This study, based on a methodology that controls for most of the risks of blas Inherent to field efficacy measurement, confirms the protective capacity of neonatal BCG against childhood tuberculosis. Therefore BCG vaccination at birth must remain a public health priority especially In countries with high incidence of the disease.

Keywords tuberculosis, BCG vaccination, newborn, vaccination efficacy

Revised 1 March 1995


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. Dietrich, R. Billeskov, T. M. Doherty, and P. Andersen
Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection
J. Immunol., March 15, 2007; 178(6): 3721 - 3730.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Doi, H. Yamada, T. Yajima, W. Wajjwalku, T. Hara, and Y. Yoshikai
H2-M3-Restricted CD8+ T Cells Induced by Peptide-Pulsed Dendritic Cells Confer Protection against Mycobacterium tuberculosis
J. Immunol., March 15, 2007; 178(6): 3806 - 3813.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.